BioSpace5d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
mic5d
A Nasal Spray For Depression? FDA Gives Its Approval
This innovative treatment is poised to change the landscape of depression management ... making effective treatments crucial. Spravato is derived from ketamine, a drug that has gained attention ...
GlobalData on MSN5d
J&J’s Spravato receives FDA label expansion for depression monotherapy
The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
FiercePharma5d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Boing Boing on MSN2d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...